77 related articles for article (PubMed ID: 34009286)
1. Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient.
Lohr B; Niemann D; Verheyen J
Clin Infect Dis; 2021 Dec; 73(11):2144-2145. PubMed ID: 34009286
[No Abstract] [Full Text] [Related]
2. Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection.
Boussen I; Salmona M; Sicre De Fontbrune F; Xhaard A; De Castro N; Delaugerre C; Chaix ML; Molina JM
Antivir Ther; 2024 Feb; 29(1):13596535221097495. PubMed ID: 38353416
[TBL] [Abstract][Full Text] [Related]
3. Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient.
Sabin AP; Richmond CS; Kenny PA
Diagn Microbiol Infect Dis; 2022 May; 103(1):115656. PubMed ID: 35231807
[TBL] [Abstract][Full Text] [Related]
4. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
[TBL] [Abstract][Full Text] [Related]
5. Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro.
Widera M; Wilhelm A; Hoehl S; Pallas C; Kohmer N; Wolf T; Rabenau HF; Corman VM; Drosten C; Vehreschild MJGT; Goetsch U; Gottschalk R; Ciesek S
J Infect Dis; 2021 Oct; 224(7):1109-1114. PubMed ID: 34223909
[TBL] [Abstract][Full Text] [Related]
6. Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies.
Jary A; Marot S; Faycal A; Leon S; Sayon S; Zafilaza K; Ghidaoui E; Quoc SN; Nemlaghi S; Choquet S; Dres M; Pourcher V; Calvez V; Junot H; Marcelin AG; Soulié C
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215820
[TBL] [Abstract][Full Text] [Related]
7. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
[TBL] [Abstract][Full Text] [Related]
9. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany.
Jensen B; Luebke N; Feldt T; Keitel V; Brandenburger T; Kindgen-Milles D; Lutterbeck M; Freise NF; Schoeler D; Haas R; Dilthey A; Adams O; Walker A; Timm J; Luedde T
Lancet Reg Health Eur; 2021 Sep; 8():100164. PubMed ID: 34278371
[TBL] [Abstract][Full Text] [Related]
10. Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report.
Fenaux H; Gueneau R; Chaghouri A; Henry B; Mouna L; Roque-Afonso AM; Vauloup-Fellous C
BMC Infect Dis; 2021 Dec; 21(1):1223. PubMed ID: 34876033
[TBL] [Abstract][Full Text] [Related]
11. Bamlanivimab infusion experience at one academic emergency department.
Yoo MJ; Long BJ; Schauer SG
Am J Emerg Med; 2022 Jun; 56():266-267. PubMed ID: 34294501
[No Abstract] [Full Text] [Related]
12. Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil.
Nonaka CKV; Franco MM; Gräf T; de Lorenzo Barcia CA; de Ávila Mendonça RN; de Sousa KAF; Neiva LMC; Fosenca V; Mendes AVA; de Aguiar RS; Giovanetti M; de Freitas Souza BS
Emerg Infect Dis; 2021 May; 27(5):1522-1524. PubMed ID: 33605869
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies.
Müller K; Girl P; Giebl A; Gruetzner S; Antwerpen M; Khatamzas E; Wölfel R; von Buttlar H
Virus Genes; 2021 Dec; 57(6):502-509. PubMed ID: 34608598
[TBL] [Abstract][Full Text] [Related]
14. Bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19.
Med Lett Drugs Ther; 2021 Oct; 63(1635):163-164. PubMed ID: 35050242
[No Abstract] [Full Text] [Related]
15. Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations.
Wu L; Peng C; Yang Y; Shi Y; Zhou L; Xu Z; Zhu W
Brief Bioinform; 2022 Jan; 23(1):. PubMed ID: 34553217
[TBL] [Abstract][Full Text] [Related]
16. New-onset seizures after bamlanivimab infusion.
Jumkhawala SA; Bente JA
Br J Clin Pharmacol; 2022 Mar; 88(3):1395-1397. PubMed ID: 34532885
[No Abstract] [Full Text] [Related]
17. Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis.
Zuo L; Ao G; Wang Y; Gao M; Qi X
J Infect; 2022 Feb; 84(2):248-288. PubMed ID: 34534563
[No Abstract] [Full Text] [Related]
18. Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.
Kumar RN; Wu EL; Stosor V; Moore WJ; Achenbach C; Ison MG; Angarone MP
Clin Infect Dis; 2022 Jan; 74(1):24-31. PubMed ID: 33846730
[TBL] [Abstract][Full Text] [Related]
19. Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?
Doggrell SA
Expert Opin Biol Ther; 2021 Nov; 21(11):1359-1362. PubMed ID: 34555986
[TBL] [Abstract][Full Text] [Related]
20. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Planas D; Veyer D; Baidaliuk A; Staropoli I; Guivel-Benhassine F; Rajah MM; Planchais C; Porrot F; Robillard N; Puech J; Prot M; Gallais F; Gantner P; Velay A; Le Guen J; Kassis-Chikhani N; Edriss D; Belec L; Seve A; Courtellemont L; Péré H; Hocqueloux L; Fafi-Kremer S; Prazuck T; Mouquet H; Bruel T; Simon-Lorière E; Rey FA; Schwartz O
Nature; 2021 Aug; 596(7871):276-280. PubMed ID: 34237773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
